PT  - JOURNAL ARTICLE
AU  - Lee, Sae R.
AU  - Lee, Eun G.
AU  - Cho, Young H.
AU  - Park, Eun J.
AU  - Lee, Young-In
AU  - Choi, Jung I.
AU  - Kwon, Ryuk-Jun
AU  - Son, Soo M.
AU  - Lee, Sang Y.
AU  - Yi, Yu H.
AU  - Kim, Gyu L.
AU  - Kim, Yun J.
AU  - Lee, Jeong G.
AU  - Tak, Young Jin
AU  - Lee, Seung Hun
AU  - Ra, Young Jin
TI  - Enteropathy and intestinal malabsorption in patients treated with antihypertensive drugs. <em>A retrospective cohort study</em>
AID  - 10.15537/smj.2024.45.4.20230739
DP  - 2024 Apr 01
TA  - Saudi Medical Journal
PG  - 437--441
VI  - 45
IP  - 4
4099  - http://smj.org.sa/content/45/4/437.short
4100  - http://smj.org.sa/content/45/4/437.full
SO  - Saudi Med J2024 Apr 01; 45
AB  - Objectives: To investigate differences in the incidence of enteropathy or intestinal malabsorption in patients taking angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), and beta blockers (BBs) at a single center in Korea.Methods: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021.Results: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p=0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p=0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p=0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p=0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities.Conclusion: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs.